To summarize new pathophysiologic insights and recent advances in the treatment of intracerebral hemorrhage.
Introduction
Intracerebral hemorrhage (ICH) of nontraumatic origin is defined as the acute extravasation of blood into the brain parenchyma, occasionally extending into the ventricles, and in rare circumstances into the subarachnoid space. As the least treatable and most devastating form of stroke, ICH is a leading cause of morbidity, mortality, and disability not only in the United States but worldwide, accounting for 10%-30% of all stroke hospital admissions [1, 2] .
Primary ICH represents at least 85% of all cases and originates from the spontaneous rupture of small vessels and arterioles damaged by chronic hypertension or amyloid angiopathy. Secondary ICH is associated with vascular abnormalities such as arteriovenous malformations or aneurysms, tumors, abnormal coagulation [3,4•], and trauma [5] . ICH is characteristically seen coupled with a rapid onset of neurologic dysfunction and signs of increased intracranial pressure, such as vomiting and decreased level of consciousness. The distinction between ICH and other types of stroke cannot be based on clinical grounds alone and requires the use of CT or MRI.
Risk factors
Epidemiologic studies show that hypertension (regardless of the definition and especially if untreated), advanced age [6] , male gender, black and Japanese race/ ethnicity [7, 8] , hypocholesterolemia, high alcohol intake, and cocaine use are risk factors for this catastrophic form of stroke [9•]. The risk of ICH in association with aspirin and other antiplatelet agents has been a matter of debate. It seems that high-dose aspirin (>1225 mg/d) may contribute to increasing the risk of ICH but only among elderly people, especially if associated with untreated hypertension and episodes of epistaxis [10] . Two casecontrol studies, however, failed to demonstrate an association between the use of nonsteroidal antiinflammatory drugs and the risk of ICH [11, 12] .
Pathophysiology
The initial pathophysiologic events leading to ICH are thought to be secondary to chronic vascular changes, immediately followed by three phases: (a) hematoma formation, (b) expansion, and (c) edema (Table 1) . Hypertension is present in approximately 50%-70% of patients with primary ICH; it is the most important and prevalent risk factor and leads to chronic pathologic changes within the tunica media of small and medium-sized arterioles of 100-600 µm in diameter. This vasculopathy is termed lipohyalinosis and is characterized by (a) degeneration of medial smooth muscle cells, (b) small miliary aneurysms associated with thrombosis and microhemorrhages, (c) accumulation of nonfatty debris, and (d) hyalinization of the intima, preferentially at bifurcation points and distal portions of the vessel [2] . Commonly affected structures include the thalamus, basal ganglia, deep periventricular gray matter, pons, and cerebellum [3] . Cerebral amyloid angiopathy is the result of amyloid protein being deposited within the media and adventitia of small to medium sized vessels. Cerebral amyloid angiopathy has a predilection for leptomeningeal and penetrating vessels of the cortex, which may undergo fibrinoid change, as seen in chronic hypertension. Apolipoprotein E2 (ApoE2) and apolipoprotein E4 (ApoE4) genotypes have been found in cerebral amyloid angiopathy-associated ICH [4•].
Abrupt arterial rupture leads to rapid accumulation of blood within the brain parenchyma and an increase in local tissue pressure ( Fig. 1A) . A degree of physical destruction is conceivable and may be explained by shearing forces of the expanding hematoma [13•]. In addition to the relative mass effect, the hematoma itself induces three early pathophysiologic changes in the surrounding brain tissue: (a) neuronal and glial cell death owing to apoptosis [13•] and inflammation, (b) vasogenic edema, and (c) breakdown of the brain-blood barrier [14••,15•].
Hematoma expansion is an important cause of early neurologic deterioration, and ICH volume is a powerful predictor of outcome after primary ICH [16, 17] . However, the natural history and prognosis of ICH are not totally dependent on the volume of the hemorrhage [18, 19] . An acceptable theory is that an expanding hematoma results from persistent bleeding and/or rebleeding from a single arteriolar rupture. However, more recent evidence suggests that ICH growth may result from bleeding into a peri-ICH penumbra zone [20, 21] . Recent reports have not confirmed the existence of ischemia in the hypoperfused area in the periphery of the hematoma [22,23••].
Schellinger et al. [23••] used multisequence MRI protocols including diffusion-weighted imaging and perfusionweighted imaging and found no evidence of a perihemorrhagic and potentially salvable ischemic penumbra in hyperacute ICH. They concluded that perihemorrhagic hypoperfusion is probably a consequence of reduced metabolic demands rather than a sign of ischemia [23••]. Since ischemia may not explain the changes and degree of neurologic dysfunction that occur after the ictus, neurotoxic and inflammatory mechanisms have more recently been implicated in the pathogenesis of perihemorrhagic tissue damage. These include ( [30] also found that high plasma concentrations of proinflammatory molecules (interleukin-6, tumor necrosis factor ␣, and intercellular adhesion molecule-1) within 24 hours of ICH onset are significantly correlated with the magnitude of subsequent perihematomal edema. This supports the findings of previous experiments in which administration of interleukin-1 and tumor necrosis ␣ induces opening of the blood-brain barrier, leading to vasogenic edema [31, 32] . Activation of the complement cascade leads to cell membrane destruction and glutamate excretion ( Fig. 1) . Transient accumulation of high levels of glutamate and other amino acids have been observed within the perihematoma region of rat brains in experimental models of ICH and constitute markers of excitotoxicity [14••,30] . Interruption of the inflammatory cascade by complement-complex inhibitors has been shown to reduce brain swelling in experimental ICH [33] . Interestingly, release of interleukin-1␤ is associated with hyperglycemia and worsening brain edema in rats [34••] . Hyperglycemia may play a role in the early physiopathology of edema formation as an osmotic force driving water into the extracellular space. Furthermore, hyperglycemia is a predictor of 30-day mortality in human studies of ICH [18, 19] .
Additional animal and human studies [15•,26•] have also shown evidence of an overwhelming hematoma-induced inflammatory response. The upregulation of matrix metalloproteinases, a family of proteases involved in several neuropathologic conditions and primarily responsible for extracellular matrix remodeling, chemotaxis, and proteolytic cleavage of precursor molecules, is seen in ICH. The harmful effects of metalloproteinases are manifested by triggering apoptotic cellular responses, which result from cell detachment and loss of integrin signaling [13] . These effects are reduced by treatment with an endogenous inhibitor of metalloproteinases, the tissue inhibitor of metalloproteinase [15•]. Whether metalloproteinases and tissue inhibitor of metalloproteinases directly influence neuronal survival in ICH is still unclear.
Intracerebral blood is in part directly responsible for the formation of local edema after ICH. Studies in pigs have proved the deleterious effects of experimental injection of blood and its degradation products into the brain parenchyma. When whole blood was infused into cerebral lobes of anesthetized animals, perihematoma edema developed within 1 hour. Conversely, when only red blood cells where injected, edema developed after 72 hours [28, 35, 36] . Further studies have shown that elements of the coagulation cascade such as thrombin and fibrin [27,28••,37••] potentiate brain edema formation and that the use of heparinized blood had a protective effect [35, 38] . The inhibition of thrombin by argatroban proved effective in reducing the amount of perihematomal edema in rats [37••]. Of potential importance is the platelet-induced activation/release of thrombin and vascular endothelial growth factor after ICH [25•]. Vascular endothelial growth factor increases vascular permeability and vasodilation via nitric oxide induction and in turn may serve as a potential fuel for free radical generation, an important mediator of cell membrane damage. Finally, metabolism of hemoglobin by heme oxygenase after red blood cell lysis results in the release of iron, carbon monoxide, and biliverdin (Fig. 1) . The inhibition of heme oxygenase is associated with attenuation of brain edema after ICH [28••,35,36] .
These observations suggest that hyperacute edema may be caused by serum elements leading to oncotically driven water extravasation. Subsequent edema (>24 hours) may be initially caused by cytotoxic mechanisms, activation of the coagulation cascade, thrombin release, followed by subsequent release of blood degradation products, leading to breakdown of the blood-brain barrier (Table 2) . Overall, studies have demonstrated a strong correlation between serum and tissue levels of these mediators and outcome in humans or animals subjected to experimentally induced ICH [29•].
Prognosis
The mortality of ICH is 30%-40% at 30 days and 47% at 1 year [39, 40] . Factors that consistently predict mortality or adverse outcomes in ICH have been studied extensively. Independent predictors for 30-day and 1-year mortality include Glasgow Coma Scale and/or depressed level of consciousness, age, ICH volume, presence of IVH, and infratentorial origin [19, 40] .
The ICH score ( 
Current therapy of intracerebral hemorrhage
The basic neurointensive care of a patient with ICH starts with proper control of the airway, breathing, and circulation. To maintain an adequate oxygenation and 
Apoptosis
Matrix metalloproteinases Glutamate and amino acids gas exchange, emergent intubation and mechanical ventilation must be achieved in those comatose patients who are at risk of aspiration or unable to maintain a patent airway. Intubation also allows potentially useful ventilatory techniques such as hyperventilation for the treatment of intracranial hypertension. High and low blood pressure should be immediately corrected to decrease hematoma expansion and edema formation and to keep an adequate cerebral perfusion pressure. Resuscitation with isotonic fluids and vasopressors is indicated in those patients in shock. Placement of a central venous line and an arterial line help to monitor hemodynamic parameters. In addition to controlling the airway, breathing, and circulation, a detailed laboratory evaluation should be obtained including biochemical, hematologic, and coagulation profiles. Use of platelets, cryoprecipitates, and fresh frozen plasma are indicated in cases of bleeding disorders. Surgical management is still controversial, except for large cerebellar hematomas. However, if an intraventricular hemorrhage with hydrocephalus is present, prompt placement of a ventricular drain may be lifesaving. Additional measures in the ICU include nutritional support, gastrointestinal prophylaxis, and deep venous thrombosis prophylaxis, which is not contraindicated acutely in ICH. Guidelines for the management of ICH have been reviewed elsewhere [42] .
Ultra early hemostatic therapy
Rapid correction of coagulopathy and enhancing coagulation parameters in normal patients may play an important role in early ICH management. Recombinant activated factor VII (rFVIIa, NovoSeven; NovoNordisk A/S, Copenhagen, Denmark), a powerful initiator of hemostasis approved for the treatment of bleeding in patients with hemophilia, may also promote hemostasis in pa-tients with normal coagulation [16] . A small preliminary trial of -␣-caproic acid on early hemostatic therapy for ICH has been conducted with negative results [42a] . As an initiative to answer the American Heart Association's call to execute well-designed studies to investigate new treatments for ICH, the NovoSeven ICH Trial is currently underway. This randomized, double-masked, placebo-controlled, dose-ranging study will test the hypothesis that rFVIIIa given within 4 hours of onset can prevent or minimize hematoma growth in patients with ICH and normal coagulation [16] .
Intracranial pressure monitoring, cerebral edema, and osmotherapy
The knowledge that we possess in this area is derived primarily from clinical experience and animal experiments. Qureshi et al. [43, 44•] demonstrated the effectiveness of 23.4% saline solution over 10% saline and mannitol during imminent transtentorial herniation in a canine model of ICH. Apart from a negative trial of glycerol [45] given within 48 hours of ICH onset, no prospective, randomized, controlled trials have compared the effectiveness of the different osmotic agents available for the management of increased intracranial pressure in ICH.
Seizures
The electroencephalographic pattern in ICH is characterized by prominent polymorphic activity, disruption of posterior ␣ rhythm, excessive slow activity, and occasional lateralization [46] . The 30-day risk of seizures after ICH is approximately 8% [47] . Epileptogenic activity may progress to convulsive or nonconvulsive seizures in as many as 28% of the patients, worsening neuronal injury and complicating the clinical status of an already critically ill patient. Overt convulsive status epilepticus is seen in 1%-2% of the patients [47] , and the risk of epilepsy is approximately 5%-27% [47] . Lobar location and small hematomas are independent predictors of early seizures [47] . Patients with ICH may benefit from prophylactic antiepileptic therapy, but no randomized trial has addressed the utility of antiepileptic drugs in the setting of ICH.
Achieving normothermia
Hyperthermia has been associated with adverse outcomes in several conditions including ischemic stroke. Szczudlik et al. [41] showed that ICH patients with onset of hyperthermia on the first day of hospitalization have greater mortality and worse functional status 30 days after the ictus. However, it was not an independent risk factor for mortality. The American Heart Association has recommended normothermia in the setting of acute ICH [42] . However, no method to accomplish this has been evaluated in a prospective fashion. Although acetaminophen and cooling blankets are generally used, their efficacy in the intensive care setting has been questioned. 
Modulation of inflammatory response
Argatroban, a potent inhibitor of fibrin-bound and free thrombin, has been used successfully as an alternative for anticoagulation in patients with heparin-induced thrombocytopenia, acute ischemic stroke, and vascular occlusive disease. Animal models have shown that this agent reduces brain edema within 6 hours of administration and therefore may be an effective therapy for hematoma-induced edema [37] . Clinical trials of this and other antiinflammatory strategies for ICH are currently in the planning stages.
Emergency craniotomy and clot removal
The results of studies addressing surgical management for supratentorial ICH have shown no benefit [50] . A recent retrospective, highly selective study showed better functional independence in 22% of patients with worsening neurologic examination but with intact brainstem reflexes [52] . Intraclot recombinant tissue plasminogen activator administration proved effective for volume reduction but was associated with worsening brain edema in a pig model of ICH [51] . The STICH Trial, a large, randomized trial of open craniotomy within 72 hours of ICH onset, is currently underway (D. Mendelow, personal communication).
Conclusion
Emerging information of the physiopathologic mechanisms of injury that occur after ICH is available from recent animal models and human studies. The effects of chronic vascular changes, hematoma formation, hypoperfusion, humoral and cellular toxicity from coagulation and products of blood degradation, inflammatory mediators, and apoptosis may all play a role in the physiopathology of ICH-related perihematomal tissue injury. Novel clinical trials based on these insights are needed.
